Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by Profund Advisors LLC

Profund Advisors LLC increased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 11.7% in the 4th quarter, HoldingsChannel reports. The firm owned 28,589 shares of the biopharmaceutical company’s stock after buying an additional 2,996 shares during the quarter. Profund Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $3,293,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of ALNY. Huntington National Bank purchased a new stake in Alnylam Pharmaceuticals in the 4th quarter worth approximately $34,000. Exchange Traded Concepts LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at $44,000. Sowell Financial Services LLC grew its stake in shares of Alnylam Pharmaceuticals by 1,992.0% during the 4th quarter. Sowell Financial Services LLC now owns 523 shares of the biopharmaceutical company’s stock valued at $60,000 after buying an additional 498 shares during the period. Harel Insurance Investments & Financial Services Ltd. grew its stake in shares of Alnylam Pharmaceuticals by 333.3% during the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 572 shares of the biopharmaceutical company’s stock valued at $66,000 after buying an additional 440 shares during the period. Finally, Emerald Mutual Fund Advisers Trust purchased a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at $115,000. Hedge funds and other institutional investors own 93.83% of the company’s stock.

ALNY has been the subject of several research reports. BidaskClub raised shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Evercore ISI began coverage on shares of Alnylam Pharmaceuticals in a report on Friday, February 7th. They set a “buy” rating and a $145.00 target price on the stock. Cowen restated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Thursday, March 5th. Piper Jaffray Companies lifted their target price on shares of Alnylam Pharmaceuticals from $145.00 to $155.00 and gave the company an “overweight” rating in a report on Tuesday, December 17th. Finally, Piper Sandler restated a “buy” rating and set a $155.00 target price on shares of Alnylam Pharmaceuticals in a report on Tuesday, March 3rd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Alnylam Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $132.63.

ALNY stock traded up $8.43 during trading on Thursday, reaching $107.21. The stock had a trading volume of 824,328 shares, compared to its average volume of 783,461. Alnylam Pharmaceuticals, Inc. has a 1-year low of $65.81 and a 1-year high of $134.51. The company has a current ratio of 4.87, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $11.30 billion, a P/E ratio of -13.17 and a beta of 2.22. The firm has a fifty day moving average price of $116.18 and a 200 day moving average price of $105.25.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported ($2.47) EPS for the quarter, missing analysts’ consensus estimates of ($2.25) by ($0.22). Alnylam Pharmaceuticals had a negative return on equity of 55.82% and a negative net margin of 403.24%. The firm had revenue of $71.70 million during the quarter, compared to analyst estimates of $71.45 million. During the same quarter in the prior year, the firm earned ($1.82) EPS. The business’s quarterly revenue was up 241.4% compared to the same quarter last year. Sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -7.2 EPS for the current year.

In other Alnylam Pharmaceuticals news, CEO John Maraganore sold 34,765 shares of the business’s stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $131.85, for a total value of $4,583,765.25. Following the transaction, the chief executive officer now owns 224,758 shares in the company, valued at approximately $29,634,342.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Steven M. Paul sold 30,000 shares of the business’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $130.00, for a total transaction of $3,900,000.00. Following the completion of the transaction, the director now owns 31,000 shares in the company, valued at approximately $4,030,000. The disclosure for this sale can be found here. Insiders sold a total of 151,989 shares of company stock worth $19,091,758 in the last quarter. 3.60% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.

Further Reading: Marijuana Stocks Investing Considerations

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.